Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03850548
Recruitment Status : Completed
First Posted : February 22, 2019
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Eugénie MABRUT, Hospices Civils de Lyon

Brief Summary:
Osteaoarticular infection due to C. acnes are known to be of late onset, causing chronic infection possibly pauci-symptomatic. Osteaoarticular infection due to C. acnes represents a diagnostic challenge, since C. acnes is slow and difficult to grow, and can also be considered a contaminant.A 16S universal PCR bacteriological diagnosis has been proposed but is lacking of sensitivity. A specific C. acnes PCR was developed in 2010, but is not used routinely.

Condition or disease Intervention/treatment
Bone and Joint Infection Other: Prosthetic joint infection with Cutibacterium acnes

Layout table for study information
Study Type : Observational
Actual Enrollment : 6 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR : Descriptive Study of 6 Patients
Actual Study Start Date : January 1, 2016
Actual Primary Completion Date : March 1, 2017
Actual Study Completion Date : February 1, 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Prosthetic joint infection with Cutibacterium acnes
Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
Other: Prosthetic joint infection with Cutibacterium acnes
patients having a prosthesis infection with C.acnes identified by specific PCR




Primary Outcome Measures :
  1. Rate of diagnostic delay [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]
    time between surgery and detection of C. acnes by PCR


Secondary Outcome Measures :
  1. rate of radiologic signs [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]
    prosthesis loosening or not

  2. rate of duration of antibiotherapy [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]
    measures of duration of the antibiotherapy

  3. rate of use of this diagnostic [ Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption ]
    descriptions of patients managed with this diagnostic



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
patients having had infection prothesis vith C. acnes identified by PCR and managed at the croix rousse hospital
Criteria

Inclusion Criteria:

  • patients having had infection prothesis vith C. acnes identified by PCR

Exclusion Criteria:

  • none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03850548


Locations
Layout table for location information
France
Hospices Civils de Lyon
Lyon, France, 69004
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Layout table for investigator information
Study Director: Tristan Ferry, Md,PhD HCL

Layout table for additonal information
Responsible Party: Eugénie MABRUT, clinical research assistant, Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03850548     History of Changes
Other Study ID Numbers: 18-031
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Eugénie MABRUT, Hospices Civils de Lyon:
bone and joint infection
Propionibacterium acnes
Cutibacterium acnes

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases